Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
O14744

UPID:
ANM5_HUMAN

ALTERNATIVE NAMES:
72 kDa ICln-binding protein; Histone-arginine N-methyltransferase PRMT5; Jak-binding protein 1; Shk1 kinase-binding protein 1 homolog

ALTERNATIVE UPACC:
O14744; A8MTP3; A8MZ91; B4DX49; B4DY30; B5BU10; D3DS33; E2QRE7; Q6IBR1; Q9UKH1

BACKGROUND:
The enzyme Protein arginine N-methyltransferase 5, known for its roles in the methylation of arginine residues, is pivotal in the assembly of snRNP particles, regulation of transcriptional elongation, and modulation of signal transduction pathways. By methylating histones and non-histone proteins, PRMT5 plays a critical role in the epigenetic control of gene expression and impacts cellular proliferation and differentiation.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Protein arginine N-methyltransferase 5 offers a pathway to novel therapeutic interventions. Given its central role in epigenetic modifications and signal transduction, targeting PRMT5 could provide innovative treatments for conditions where these processes are disrupted.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.